IL289188B2 - Protein-enveloped polymeric micelle - Google Patents

Protein-enveloped polymeric micelle

Info

Publication number
IL289188B2
IL289188B2 IL289188A IL28918821A IL289188B2 IL 289188 B2 IL289188 B2 IL 289188B2 IL 289188 A IL289188 A IL 289188A IL 28918821 A IL28918821 A IL 28918821A IL 289188 B2 IL289188 B2 IL 289188B2
Authority
IL
Israel
Prior art keywords
anhydride
group
protein
micelles
integer
Prior art date
Application number
IL289188A
Other languages
English (en)
Hebrew (he)
Other versions
IL289188B1 (en
IL289188A (en
Original Assignee
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo filed Critical Univ Tokyo
Publication of IL289188A publication Critical patent/IL289188A/en
Publication of IL289188B1 publication Critical patent/IL289188B1/en
Publication of IL289188B2 publication Critical patent/IL289188B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Variable-Direction Aerials And Aerial Arrays (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polyamides (AREA)
IL289188A 2019-06-28 2020-06-25 Protein-enveloped polymeric micelle IL289188B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868040P 2019-06-28 2019-06-28
PCT/JP2020/025086 WO2020262550A1 (ja) 2019-06-28 2020-06-25 タンパク質内包高分子ミセル

Publications (3)

Publication Number Publication Date
IL289188A IL289188A (en) 2022-02-01
IL289188B1 IL289188B1 (en) 2025-01-01
IL289188B2 true IL289188B2 (en) 2025-05-01

Family

ID=74060587

Family Applications (2)

Application Number Title Priority Date Filing Date
IL289188A IL289188B2 (en) 2019-06-28 2020-06-25 Protein-enveloped polymeric micelle
IL317420A IL317420A (en) 2019-06-28 2020-06-25 Protein-enveloped polymeric micelle

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL317420A IL317420A (en) 2019-06-28 2020-06-25 Protein-enveloped polymeric micelle

Country Status (8)

Country Link
US (2) US12702718B2 (cg-RX-API-DMAC7.html)
EP (1) EP3992229A4 (cg-RX-API-DMAC7.html)
JP (3) JP7083206B2 (cg-RX-API-DMAC7.html)
CN (2) CN114080412B (cg-RX-API-DMAC7.html)
AU (1) AU2020305308B2 (cg-RX-API-DMAC7.html)
CA (1) CA3144358A1 (cg-RX-API-DMAC7.html)
IL (2) IL289188B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020262550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114080412B (zh) 2019-06-28 2023-08-25 国立大学法人东京大学 蛋白质内包高分子胶束
JP7857657B2 (ja) * 2022-01-12 2026-05-13 国立大学法人 東京大学 サイトカイン内包高分子ミセル
EP4536679A1 (en) * 2022-06-11 2025-04-16 The University Of Tokyo Nucleic acid closing polymeric micelle
JP2024130632A (ja) * 2023-03-15 2024-09-30 国立大学法人 東京大学 タンパク質送達用pH応答性担体
JP2024130631A (ja) * 2023-03-15 2024-09-30 国立大学法人 東京大学 pH応答性タンパク質送達用担体
CN117924695A (zh) * 2024-01-23 2024-04-26 中国科学院深圳先进技术研究院 一种基于聚氨基酸载体的核酸药物递送体系及其制备方法和应用
WO2025229172A1 (en) 2024-05-03 2025-11-06 Institut National de la Santé et de la Recherche Médicale Live cell encapsulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082198A1 (en) * 1995-01-10 2002-06-27 Yasuhisa Sakurai Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
US8211468B2 (en) 1999-06-07 2012-07-03 Arrowhead Madison Inc. Endosomolytic polymers
US8541548B2 (en) 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CN1981873A (zh) 2000-06-09 2007-06-20 莱古伦公司 制备微胶粒的方法和所述微胶粒的用途
US6797704B2 (en) 2000-10-06 2004-09-28 The Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
PL369953A1 (en) 2001-10-13 2005-05-02 Asterion Limited Glycosylphosphatidylinositol containing polypeptides
US20030147958A1 (en) 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
EP1506218B1 (en) * 2002-05-24 2017-04-12 Arrowhead Pharmaceuticals, Inc. Reversible modification of membrane interaction
US20040162235A1 (en) * 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
WO2008104994A2 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
DK2152293T3 (en) 2007-05-11 2017-02-06 Univ Nebraska COMPOSITIONS FOR PROTEIN GIVING AND PROCEDURES FOR USE THEREOF
EP2272897B1 (en) 2008-03-10 2016-12-28 The University of Tokyo Copolymer including uncharged hydrophilic block and cationic polyamino acid block having lateral chain to which hydrophobic radical is partially introduced, and use of copolymer
WO2010106700A1 (ja) 2009-03-17 2010-09-23 国立大学法人東京大学 タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体
CN102971002B (zh) 2010-07-09 2019-04-05 国立大学法人东京大学 核酸递送用组合物及载体组合物、使用其的药物组合物以及核酸递送方法
WO2012173784A1 (en) 2011-06-17 2012-12-20 Arrowhead Madison Inc. Disubstituted maleic anhydrides with altered kinetics of ring closure
JP6799823B2 (ja) 2015-04-16 2020-12-16 国立大学法人 筑波大学 ポリ(l−アルギニン)セグメント含有ブロック共重合体とポリアニオン性ポリマーのポリイオンコンプレックス
WO2017078883A1 (en) 2015-11-06 2017-05-11 3M Innovative Properties Company Redox polymerizable composition with photolabile transition metal complexes
CN109642024A (zh) * 2016-08-02 2019-04-16 日本化药株式会社 主动靶向型高分子衍生物、包含该高分子衍生物的组合物以及它们的用途
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CN121136065A (zh) 2018-04-27 2025-12-16 基因编辑有限公司 阳离子聚合物和用于生物分子递送的用途
CN109842024A (zh) 2019-02-25 2019-06-04 徐秀焕 一种雨水散热的新型配电柜
AU2020253356A1 (en) 2019-03-29 2021-10-28 Torque Therapeutics, Inc. Immunotherapeutic compositions and use thereof
MX2022000045A (es) 2019-06-26 2022-04-20 Biorchestra Co Ltd Nanoparticulas micelares y sus usos.
CN114080412B (zh) 2019-06-28 2023-08-25 国立大学法人东京大学 蛋白质内包高分子胶束
AU2021260989A1 (en) 2020-04-22 2022-11-17 Novartis Ag Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetIL-15)
AR122446A1 (es) 2020-04-29 2022-09-14 Medimmune Llc Composiciones y métodos para suministrar agentes farmacéuticamente activos
WO2021242917A1 (en) 2020-05-27 2021-12-02 Georgetown University Targeting the cholecystokinin-b receptor for imaging and early detection of pancreatic cancer and pre-cancerous lesions
AU2021347147A1 (en) 2020-09-22 2023-05-18 Barinthus Biotherapeutics North America, Inc. Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
KR20240004403A (ko) 2021-03-29 2024-01-11 오디 쎄라퓨틱스 리미티드 단백질-거대분자 접합체 및 이의 사용 방법
FR3122573B1 (fr) 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine
WO2023116702A1 (zh) 2021-12-21 2023-06-29 华南理工大学 pH敏感的破膜聚肽及其应用
JP7857657B2 (ja) 2022-01-12 2026-05-13 国立大学法人 東京大学 サイトカイン内包高分子ミセル
EP4536679A1 (en) 2022-06-11 2025-04-16 The University Of Tokyo Nucleic acid closing polymeric micelle
CN116139104A (zh) 2022-11-29 2023-05-23 深圳先进技术研究院 一种靶向性仿生聚多肽纳米递送载体、纳米核酸递送系统及其制备方法和应用
CN116284759B (zh) 2022-11-29 2025-02-11 深圳先进技术研究院 一种聚多肽基因载体及其制备方法和应用
JP2024130631A (ja) 2023-03-15 2024-09-30 国立大学法人 東京大学 pH応答性タンパク質送達用担体
JP2024130632A (ja) 2023-03-15 2024-09-30 国立大学法人 東京大学 タンパク質送達用pH応答性担体
CN116270541B (zh) 2023-03-28 2025-04-29 中山大学 抗铜绿假单胞菌感染的纳米粒及制备方法和肺部吸入制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082198A1 (en) * 1995-01-10 2002-06-27 Yasuhisa Sakurai Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEFFERNAN, MICHAEL ET AL, DISULFIDE-CROSSLINKED POLYION MICELLES FOR DELIVERY OF PROTEIN THERAPEUTICS., 10 June 2009 (2009-06-10) *

Also Published As

Publication number Publication date
EP3992229A1 (en) 2022-05-04
IL289188B1 (en) 2025-01-01
WO2020262550A1 (ja) 2020-12-30
US20250242047A1 (en) 2025-07-31
AU2020305308B2 (en) 2026-04-09
IL317420A (en) 2025-02-01
JP2022122912A (ja) 2022-08-23
US12611465B2 (en) 2026-04-28
US20220249689A1 (en) 2022-08-11
CA3144358A1 (en) 2020-12-30
EP3992229A4 (en) 2023-05-31
CN114080412B (zh) 2023-08-25
JP2026010025A (ja) 2026-01-21
CN117024749A (zh) 2023-11-10
AU2020305308A1 (en) 2022-01-27
IL289188A (en) 2022-02-01
US12702718B2 (en) 2026-08-11
JPWO2020262550A1 (cg-RX-API-DMAC7.html) 2020-12-30
CN114080412A (zh) 2022-02-22
JP7083206B2 (ja) 2022-06-10

Similar Documents

Publication Publication Date Title
US12611465B2 (en) Protein-enclosing polymeric micelle
Tao et al. Polymeric micelles loading proteins through concurrent ion complexation and pH‐cleavable covalent bonding for in vivo delivery
US9051354B2 (en) Protein charge regulator and protein-encapsulating polymer micelle complex
US20250177545A1 (en) Cytokine-encapsulating polymeric micelle
Andrianov Noncovalent PEGylation of protein and peptide therapeutics
JPWO2008010341A1 (ja) 生理活性ポリペプチドまたはタンパク質内包高分子ポリマーミセルおよびその製造方法
WO2020241819A1 (ja) 複合体、医薬、癌治療剤、キット及び結合体
WO2003037915A1 (en) Biocompatible polymers including peptide spacer
JP6292632B2 (ja) ポリカチオン性トリブロックコポリマーとポリアニオン性ポリマーと生理活性ペプチドを含む組成物
AU2022238918A1 (en) Dendritic peptide conjugated polymers for efficient intracellular delivery of nucleic acids to immune cells
WO2024190929A1 (ja) タンパク質送達用pH応答性担体
JPWO2018025699A1 (ja) アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途
WO2024190928A1 (ja) pH応答性タンパク質送達用担体
US20240033374A1 (en) Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof
CN120329466A (zh) 一种抗蛋白粘附的细胞亲和性两性离子聚合物及其应用
Ibrahimova Development of polypeptide-based multifunctional nano-assemblies for a theranostic approach
CN111704705A (zh) 一种嵌段聚合物及其制备方法以及一种载药囊泡和靶向载药囊泡
Lu Zwitterionic Polymer For Drug Delivery Applications
Vusala Development of Polypeptide-Based Multifunctional Nano-Assemblies for a Theranostic Approach
Özer The effect of architecture and molecular weight on cell uptake and intracellular distribution of poly (ethylene glycol)